NUON Completes 10:1 Free Capital Reduction at Telcon RF Pharmaceutical with No Change in Ownership Percentage
This report is a major shareholding change report filed by NUON, the largest shareholder of Telcon RF Pharmaceutical, as of June 30, 2026. The key change is a 10:1 free capital reduction.
The reduction decreased total outstanding shares from 71,523,533 to 7,152,353 shares, a 90% decrease, but NUON and its related parties retained their 21.57% ownership stake, resulting in no dilution for existing shareholders.
NUON holds loan agreements with related party L2L Holdings, secured by 144,642 shares as collateral. The contracts were extended until 2030, but financial impact is negligible.
[AI Summary]This capital reduction is a financial measure to improve Telcon RF Pharmaceutical's capital structure. Despite the 90% share consolidation, the largest shareholder's stake remains unchanged, preserving relative shareholder value. While near-term price surges are unlikely, the move signals financial health improvement and potential deficit reduction.